Researchers have revealed the first vaccine purely designed by artificial intelligence (AI). This has the potential to revolutionise the drug discovery process by making it quicker, cheaper and producing more effective drugs. From target discovery to market, the drug discovery process takes on average nine years and millions of dollars. The majority of this time […]
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
The pharmaceutical industry is capturing an ever-increasing quantity of data, but this is often underutilised by professionals in the perfect place to use this data to their advantage. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or miss […]
Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.
The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by […]
Takeda Pharmaceutical has announced the sizeable first sale in its proposed £10 billion-worth of assets to offset the debt it took on during its acquisition of Shire. The company announced it was divesting eye drug Xiidra to Novartis for $5.3bn total, and its TachoSil Fibrin Sealant Patch to Ethicon for $400 million in case.
Two companies with access to data from the 100,000 Genomes Project have identified patients with previously undiscovered life-threatening kidney and neurological diseases. The companies, Alexion and BioMarin, were part of Genomic England’s Discovery Forum, which grants certain industry research proposals access to data from the project after vetting.
Two separate studies have uncovered insights into why checkpoint-inhibiting immune-oncology (IO) drugs only work for a minority of patients, even when combined with other treatments. The first study uncovered a resistance mechanism within the gut microbiome, while the other relates to cancer cell-produced vesicles.
An FDA-approved drug to treat severe asthma also drastically improves the health of those individuals with hypereosinophilic syndromes (HES), rare types of chronic immune disorders. A larger placebo-controlled trial of the drug, benralizumab, will now be undertaken to confirm the results.
AstraZeneca has signed a $6.9 billion deal with Daiichi Sankyo for a single antibody-drug conjugate (ADC), trastuzumab deruxtecan.
University of Alberta researchers have discovered an experimental combination drug therapy which dramatically shrinks tumours and prevents metastasis in mice, and could act as a new cancer therapy in the future.
Out of a whole host of engaging and enjoyable moments at Front Line Genomics’ recent Data Driven Drug Development (D4) conference, held in Boston on 20-21 March, one of the most memorable was definitely the triumph of nQ Medical in our innovation showcase, beating out three other contenders for the claim to be “most innovative” of the technologies on display.
Biogen has announced it will acquire Nightstar Therapeutics for around $800m, providing the pharma giant with a pipeline of gene therapy candidates for ophthalmology.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.